J&J to impose new limits on 340B access after industry court win
One pharma giant is implementing some major restrictions on access to 340B drugs, which go into effect next month.
Johnson & Johnson announced last week that it is updating its 340B policy effective Mar. 7, which will include restricting non-grantee covered entities to only one contract pharmacy to dispense outpatient drugs covered under 340B. The policy, which includes whether the approved health centers and hospitals have an in-house pharmacy or not, set the conditions that they must provide limited claims data, and that the one contract pharmacy must be within 40 miles of the approved health care entity’s parent site.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters